Introduction Various types of delivery systems, including organic/inorganic nanoparticles, small molecule targeting moieties, and antibodies, have been explored as carriers for PROTACs. These systems play a crucial role in addressing the challengesRead More…
PROTAC is Moving Towards Clinical Application of Oncology—II
Preclinical evidence of PROTAC The breakthrough in PROTAC’s design paves the way for its early clinical trials. According to statistics, as of January 8, 2023, 18 kinds of PROTAC were conducting phaseRead More…
PROTAC is Moving Towards Clinical Application of Oncology—I
PROTAC uses the natural mechanism of protein degradation in cells, that is, the ubiquitin-protease system, to induce targeted protein degradation. Compared with traditional small molecular inhibitors used in cancer therapy, PROTAC hasRead More…
Change the Logic of PROTAC Research and Development to Get the Latest Progress
Recently, the Li Zigang and Yin Feng research group of Shenzhen Graduate School of Peking University published a research paper entitled “Targeted biomolecule regulation platform: a Split-and-Mix PROTAC approach” in Journal ofRead More…
Pro-PROTAC with Different Conditional Response—II
Enzyme-Catalyzed Responsive Pro-PROTAC The researchers concentrated on the distinction between the tumor microenvironment and the normal cell environment and incorporated the endogenous enzyme response chemistry of tumor cell characteristics into the molecularRead More…
Pro-PROTAC with Different Conditional Response—I
Chemical protein degradation methods like protein degradation targeted chimera (PROTAC) allow for the simultaneous targeting of E3 ligase and disease-related proteins, with the latter then being degraded by the body’s own ubiquitin-proteaseRead More…
Research Progress of PROTAC in the Development of Antineoplastic Drugs
Compared with traditional drugs, PROTAC molecules have many advantages. PROTAC molecule is covalently linked by the target protein ligand and E3 ubiquitin ligase ligand. After binding to the target protein, E3 ligaseRead More…
Cell: Targeted Degradation of Carcinogen NAMPT by PROTAC
PROTAC technology, by linking E3 ubiquitin ligase to the target protein, leads to the ubiquitin modification of the target protein which is broken down into peptides and amino acids by proteasome. AfterRead More…
PROTAC Therapy—A New Targeted Therapy for Lung Cancer
New lung cancer diagnoses and deaths have decreased as a result of reduced smoking and advances in early screening and treatment. However, lung cancer remains the leading cause of cancer deaths, accountingRead More…
Nature Sub-journal: Novel PROTAC for Precise Breast Cancer Treatment
Protein degradation targeted chimera (PROTAC) can efficiently degrade disease-causing proteins to treat varieties of diseases and has been widely investigated by global researchers. Despite of its promising prospects, the pharmacokinetic behavior ofRead More…